By Rachel Slajda ( June 5, 2012, 8:39 PM EDT) -- Would a drug by any other name sell as sweet? That's the big question as the U.S. Food and Drug Administration considers whether to make biosimilars take names different from their brand-name counterparts, and experts say the decision will have a big impact on the bottom lines of generics makers, brand-name drug companies and insurers. ...
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.